| 1 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab (Kevzara) | [4]  Abatacept Abatacept, Rituximab, Sarilumab (Kevzara), Tocilizumab | [4]  Tocilizumab 
                
                    Tocilizumab
                
            , 
                
                    Rituximab
                
            , 
                
                    Abatacept
                
            , 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [4]  CD80 CD80, CD86, IL6R, MS4A1 💬
 | [25]  Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | [1]  46 46 💬
 | 
| 2 | Kevzara | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2]  41 41, 46 💬
 | 
| 3 | Kevzara ® | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1]  41 41 💬
 | 
| 4 | SARILUMAB (Kevzara) | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [5]  41 41, 46, 84, 107, 271 💬
 | 
| 5 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1]  46 46 💬
 | 
| 6 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1 | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1]  84 84 💬
 | 
| 7 | Sarilumab SAR153191 (Kevzara) | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1]  41 41 💬
 | 
| 8 | Sarilumab SAR153191 (REGN88) (Kevzara) | [1]  Sarilumab Sarilumab (Kevzara) | [1]  Sarilumab 
                
                    Sarilumab
                
             (Kevzara) 💬
 | [1]  IL6R IL6R 💬
 | [12]  Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2]  46 46, 107 💬
 |